Tonix Pharmaceuticals announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,097,183 to the Company on September 24, 2024. The patent, entitled “Pharmaceutical Composition for Treating Migraine”, claims use of a pre-filled autoinjector comprising a composition of Zembrace SymTouch for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to provide protection into 2036.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Highlights TNX-102 SL at Global Pharmaceutics Conference
- Tonix Pharmaceuticals announces data presentations on TNX-102 SL
- Tonix Pharmaceuticals files $300M mixed securities shelf
- Tonix Pharma Secures Patent, Eyes Migraine Market Growth
- Tonix Pharmaceuticals announces issuance of U.S. patent on Tosymra